🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
0.6277
-0.0392 (-5.88%)
At close: Nov 20, 2026, 4:00 PM EST
0.6347
+0.0070 (1.12%)
After-hours: Nov 20, 2026, 7:37 PM EST

Allogene Therapeutics Stock Forecast

ALLO's stock price has decreased by -50.18% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 12 analysts polled by S&P Global, Allogene Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.00. The average 1-year stock price forecast is 1,333.81% higher than the current stock price, while the lowest is $4.00 (+537.25%) and the highest is $14 (+2,130.36%).

Price Target: $9.00 (+1,333.81%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.00$9.00$9.00$14
Change+537.25%+1333.8%+1333.8%+2130.4%

Analyst Ratings

The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy888888
Buy333333
Hold211111
Sell000000
Strong Sell000000
Total131212121212

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$14
BuyReiterates$14+2,130.36%Nov 10, 2026
Citi
Citi
Buy
Maintains
$4
BuyMaintains$4+537.25%Nov 10, 2026
RBC Capital
RBC Capital
Buy
Maintains
$9
BuyMaintains$9+1,333.81%Nov 6, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$10
BuyMaintains$10+1,493.12%Nov 6, 2026
J.P. Morgan
J.P. Morgan
Hold
Maintains
n/a
HoldMaintainsn/an/aAug 17, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
3.78M
Revenue Next Year
10.61M
from 3.78M
Increased by 180.53%
EPS This Year
-0.58
from -0.85
EPS Next Year
-0.61
from -0.58
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
114.09M156.00K95.00K22.00K-3.78M
Operating Income
-180.19M-335.54M-314.49M-257.48M-206.93M-207.96M
Net Income
-182.05M-340.41M-327.27M-257.59M-190.89M-191.34M
EPS
-----0.85-0.58
Free Cash Flow
-----149.63M-143.00M
No. Analysts
-----11
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High4.7M
Avg3.8M
Lown/a

Revenue Growth

Revenue Growth20272028
High
1,578.3%
Avg
180.5%
Low
-100.0%

EPS Forecast

EPS202620272028
High-0.44
Avg-0.58
Low-0.64

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-